Cormorant Asset Management’s Array Biopharma Inc ARRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-450,000
| Closed | -$20.8M | – | 79 |
|
|
2019
Q2 | $20.8M | Sell |
450,000
-50,000
| -10% | -$1.4M | 1.2% | 29 |
|
|
2019
Q1 | $12.2M | Sell |
500,000
-80,756
| -14% | -$1.68M | 0.82% | 37 |
|
|
2018
Q4 | $8.28M | Sell |
580,756
-19,244
| -3% | -$292K | 0.67% | 38 |
|
|
2018
Q3 | $9.12M | Sell |
600,000
-68,743
| -10% | -$1.05M | 0.59% | 37 |
|
|
2018
Q2 | $11.2M | Hold |
668,743
| – | – | 0.83% | 37 |
|
|
2018
Q1 | $10.9M | Sell |
668,743
-31,257
| -4% | -$501K | 0.81% | 26 |
|
|
2017
Q4 | $8.96M | Sell |
700,000
-200,000
| -22% | -$2.27M | 0.94% | 28 |
|
|
2017
Q3 | $11.1M | Hold |
900,000
| – | – | 1.95% | 18 |
|
|
2017
Q2 | $7.53M | Hold |
900,000
| – | – | 1.25% | 25 |
|
|
2017
Q1 | $8.05M | Sell |
900,000
-250,000
| -22% | -$2.66M | 1.17% | 31 |
|
|
2016
Q4 | $10.1M | Hold |
1,150,000
| – | – | 1.36% | 23 |
|
|
2016
Q3 | $7.76M | Buy |
+1,150,000
| New | +$4.45M | 0.86% | 40 |
|
|
2015
Q4 | – | Sell |
-850,000
| Closed | -$3.88M | – | 95 |
|
|
2015
Q3 | $3.88M | Hold |
850,000
| – | – | 0.62% | 44 |
|
|
2015
Q2 | $6.13M | Hold |
850,000
| – | – | 0.81% | 37 |
|
|
2015
Q1 | $6.26M | Sell |
850,000
-150,000
| -15% | -$1.07M | 0.97% | 34 |
|
|
2014
Q4 | $4.73M | Hold |
1,000,000
| – | – | 0.73% | 36 |
|
|
2014
Q3 | $3.57M | Hold |
1,000,000
| – | – | 0.73% | 37 |
|
|
2014
Q2 | $4.56M | Sell |
1,000,000
-750,000
| -43% | -$3.1M | 1.21% | 31 |
|
|
2014
Q1 | $8.22M | Hold |
1,750,000
| – | – | 1.89% | 24 |
|
|
2013
Q4 | $8.77M | Buy |
+1,750,000
| New | +$9.53M | 2.54% | 15 |
|
Other funds holding ARRY
Cormorant Asset Management's ARRY Position: Q3 2019 in Review
Cormorant Asset Management sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 450,000 shares — an estimated $20.8M sold.
Cormorant Asset Management first reported a position in ARRY in Q4 2013 and held it in 20 quarters. The position peaked at $20.8M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.
- Cormorant Asset Management reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
- Cormorant Asset Management sold 450,000 Array Biopharma Inc shares in Q3 2019, an estimated $20.8M.
- Cormorant Asset Management first reported a position in Array Biopharma Inc in Q4 2013 and held it in 20 quarters.
- Cormorant Asset Management's Array Biopharma Inc position peaked at $20.8M in Q2 2019.
- 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.
Based on Cormorant Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.